Pyxis Oncology (PYXS) Projected to Release Earnings on Thursday

Pyxis Oncology (NASDAQ:PYXS) is expected to be issuing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.34) per share and revenue of $0.0330 million for the quarter. Investors are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 12:30 PM ET.

Pyxis Oncology (NASDAQ:PYXS) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.02). On average, analysts expect Pyxis Oncology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Pyxis Oncology Stock Down 0.9%

NASDAQ PYXS opened at $3.13 on Thursday. The stock has a market capitalization of $198.29 million, a PE ratio of -2.39 and a beta of 1.31. The company has a 50 day moving average price of $2.34 and a two-hundred day moving average price of $1.89. Pyxis Oncology has a 12-month low of $0.97 and a 12-month high of $5.55.

Wall Street Analysts Forecast Growth

PYXS has been the topic of a number of recent research reports. Leerink Partners cut their price target on shares of Pyxis Oncology from $9.00 to $7.00 and set an “outperform” rating on the stock in a report on Thursday, July 2nd. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings lowered Pyxis Oncology from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. Wells Fargo & Company started coverage on Pyxis Oncology in a research report on Monday. They issued an “overweight” rating and a $12.00 price target for the company. Finally, Wedbush started coverage on Pyxis Oncology in a research note on Tuesday, May 5th. They set an “outperform” rating and a $6.00 price target for the company. Eight research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $7.50.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. OMERS ADMINISTRATION Corp bought a new stake in Pyxis Oncology during the fourth quarter valued at about $77,000. Barclays PLC lifted its position in shares of Pyxis Oncology by 1,939.3% during the 4th quarter. Barclays PLC now owns 60,385 shares of the company’s stock worth $69,000 after purchasing an additional 57,424 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in shares of Pyxis Oncology by 37.1% during the 4th quarter. Dimensional Fund Advisors LP now owns 50,066 shares of the company’s stock worth $58,000 after purchasing an additional 13,550 shares during the last quarter. Two Sigma Investments LP bought a new stake in Pyxis Oncology during the 3rd quarter valued at approximately $103,000. Finally, Qube Research & Technologies Ltd boosted its stake in Pyxis Oncology by 128.4% during the 2nd quarter. Qube Research & Technologies Ltd now owns 103,063 shares of the company’s stock valued at $113,000 after purchasing an additional 57,935 shares during the period. 39.07% of the stock is currently owned by institutional investors and hedge funds.

Pyxis Oncology Company Profile

Pyxis Oncology (NASDAQ: PYXS) is a clinical?stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody?drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off?target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early?stage ADC candidates directed against a variety of solid tumor antigens.